COGNITION THERAPEUTICS INC. - COMMON STOCK

3.1800

25-August-25 13:45:00

15 minutes delayed

Stocks

+0.3700

+13.17%

Today's range

3.0500 - 3.8300

ISIN

N/A

Source

NASDAQ

Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

26 Feb 2025 04:00:00 By Nasdaq GlobeNewswire
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

25 Feb 2025 04:30:40 By Nasdaq GlobeNewswire
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

20 Feb 2025 04:30:00 By Nasdaq GlobeNewswire
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

30 Jan 2025 04:30:33 By Nasdaq GlobeNewswire
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08 Jan 2025 13:14:32 By Nasdaq GlobeNewswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

18 Dec 2024 04:22:43 By Nasdaq GlobeNewswire
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

26 Nov 2024 04:30:22 By Nasdaq GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

25 Nov 2024 04:30:49 By Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

13 Nov 2024 04:30:45 By Nasdaq GlobeNewswire
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

12 Nov 2024 04:30:38 By Nasdaq GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 Oct 2024 13:15:00 By Nasdaq GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 Oct 2024 09:55:00 By Nasdaq GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 Oct 2024 04:30:27 By Nasdaq GlobeNewswire
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

22 Oct 2024 04:30:00 By Nasdaq GlobeNewswire
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

02 Oct 2024 04:30:00 By Nasdaq GlobeNewswire
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

01 Oct 2024 04:30:00 By Nasdaq GlobeNewswire
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

03 Sep 2024 04:30:00 By Nasdaq GlobeNewswire
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

22 Aug 2024 04:31:24 By Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

08 Aug 2024 04:00:53 By Nasdaq GlobeNewswire
Cognition Therapeutics to Report Second Quarter 2024 Financial Results

05 Aug 2024 04:30:19 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.